COMPARATIVE EFFECTIVENESS OF FRONT-LINE TREATMENTS FOR PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA WHO ARE TRANSPLANT INELIGIBLE
Author(s): ,
Thierry Facon
Affiliations:
Hôpital Claude Huriez, CHRU Lille,Lille,France
,
Jesus San-Miguel
Affiliations:
Clínica Universidad de Navarra-CIMA, IDISNA, CIBERONC,Pamplona,Spain
,
Saad Usmani
Affiliations:
Levine Cancer Institute/Atrium Health,Charlotte, NC,United States
,
Meletios A. Dimopoulos
Affiliations:
National and Kapodistrian University of Athens,Athens,Greece
,
Shaji Kumar
Affiliations:
Department of Hematology, Mayo Clinic Rochester,Rochester, MN,United States
,
Maria-Victoria Mateos
Affiliations:
University Hospital of Salamanca/IBSAL,Salamanca,Spain
,
Michele Cavo
Affiliations:
'Seràgnoli' Institute of Hematology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna,Bologna,Italy
,
Bart Heeg
Affiliations:
Ingress Health,Rotterdam,Netherlands
,
Sophie van Beekhuizen
Affiliations:
Ingress Health,Rotterdam,Netherlands
,
Marta Pisini
Affiliations:
Janssen EMEA,Beerse,Belgium
,
Sandhya Nair
Affiliations:
Janssen Research and Development,Beerse,Belgium
,
Annette Lam
Affiliations:
Janssen Global Services,Raritan, NJ,United States
,
Mary Slavcev
Affiliations:
Janssen Global Services,Raritan, NJ,United States
Jianming He
Affiliations:
Janssen Global Services,Raritan, NJ,United States
EHA Library. Facon T. Jun 15, 2019; 267012; PS1395
Prof. Thierry Facon
Prof. Thierry Facon
Contributions
Abstract

Abstract: PS1395

Type: Poster Presentation

Presentation during EHA24: On Saturday, June 15, 2019 from 17:30 - 19:00

Location: Poster area

Background
Several treatment options are available for patients with newly-diagnosed multiple myeloma (NDMM) who are transplant ineligible. Most recently, the ongoing ALCYONE and MAIA studies demonstrated significant improvement in progression-free survival (PFS) and overall response rate (ORR) for treatment with daratumumab plus bortezomib, melphalan, and prednisone (D-VMP) vs. VMP alone, and for treatment with daratumumab plus lenalidomide and dexamethasone (D-Rd) vs. Rd continuous alone, respectively (1,2). In the absence of randomized control trials (RCTs) vs. other relevant comparators, a network meta-analysis (NMA) is needed to support evidence-based decision making and ultimately help to optimize treatment and outcomes of patients with NDMM who are transplant ineligible (3).

Aims
This NMA compares daratumumab (D)-based regimens with other relevant comparators for the frontline treatment of patients with NDMM who are ineligible for transplantation.

Methods
A systematic literature review was conducted based on PubMed, EMBASE, Cochrane, the American Society of Hematology (ASH), American Society of Clinical Oncology (ASCO) and ESMO. Additional meta-analyses/reviews and ClinicalTrials.gov were further searched for potential publications that were not included in the search engines up to Dec 2018. Efficacy outcomes (i.e. the hazard ratio [HR] and 95% confidence interval [CI] for progression-free survival [PFS] and odds ratio [OR] for overall response rate [ORR]) were extracted and synthesized in an NMA. Choice of model was made on lowest deviance information criterion (DIC). Lenalidomide and dexamethasone (Rd) continuous was selected as comparator for this analysis as it was commonly included in the guidelines across regions. For PFS, HR <1 indicates the comparison is not in favor of Rd continuous whereas OR <1 is in favor of Rd continuous for ORR.

Results
Random effects results for both PFS and ORR against Rd continuous are presented in Table 1. For PFS, D-based regimens are the most favorable regimens compared to all other relevant treatment options. Compared to Rd continuous, the HR of PFS of D-VMP is 0.62 (0.21-1.84) and the HR of PFS of D-Rd is 0.55 (0.30-0.99). For PFS, in addition to the D-based regimens, VMPT-VT 0.84 (0.28-2.47) and ERd 0.83 (0.22-3.04) are the only other options that are more favorable than Rd continuous, the performance of other treatment options is less favorable than Rd continuous. Similar patterns are observed with ORR.

Conclusion
The NMA demonstrated favorable efficacy outcomes for D-based regimens including D-Rd and D-VMP vs. other relevant front-line options for patients with NDMM who are transplant-ineligible. A limitation of this analysis was that VRd, a regimen recommended by key treatment guidelines (4,5) for patients with NDMM who are transplant-ineligible, was not included as appropriate data on VRd treatment in this patient population was not available to enable inclusion into the current NMA.

References

1. Mateos MV, et al. N Engl J Med. 2018;378:518-528.

2. Facon T, et al. Presented at: American Society of Hematology Annual Meeting; December 1-4, 2018; San Diego, CA. Abstract LBA-2.

3. San-Miguel J, et al. Presented at: European Hematology Association Annual Meeting; June 14-17, 2018; Stockholm, Sweden. Abstract S107.

4. NCCN Clinical Practice Guidelines in Oncology. Multiple Myeloma Version 2.2019.

5. Moreau P, et al. Ann Oncol. 2017;28(suppl 4):iv52-iv61.

Session topic: 14. Myeloma and other monoclonal gammopathies - Clinical

Keyword(s): Meta-analysis, Multiple myeloma

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies